Tetra Bio-Pharma Inc. - TBPMF STOCK NEWS

Tetra Bio-Pharma Inc. (TSX: TBP) (OTCQB: TBPMF) announced on December 21, 2022, that it received a second Clarification Request from Health Canada regarding the Risk Management Plan for its product REDUVO™, aimed at treating chemotherapy-induced nausea and vomiting. The company will respond within the stipulated timeframe. REDUVO™, containing dronabinol, is projected to achieve 5-year cumulative gross sales of $121M. The company continues its focus on developing cannabinoid-derived drugs for various medical conditions.

Tetra Bio-Pharma announced promising results from its PIONEER clinical trial, demonstrating that ARDS-003 combined with Favipiravir may aid in treating severe COVID-19. The investigational drug ARDS-003, containing Onternabez, targets inflammatory responses linked to ARDS and Sepsis. AI-driven insights suggest that this combination could enhance treatment efficacy and reduce disease duration. The study indicates a 22% reduction in deaths for treated patients and highlights the importance of Favipiravir in improving recovery and survival rates in younger patients.

Tetra Bio-Pharma has filed three new patent applications to protect its innovative therapeutic, ARDS-003, aimed at treating acute respiratory distress syndrome (ARDS). The filings include an international application under the PCT for improving cannabinoid synthesis methods and a provisional application for crystalline Onternabez, the active agent in ARDS-003. These patents could extend intellectual property protection for up to 20 years, enhancing the company's market position in cannabinoid-derived therapies.

Tetra Bio-Pharma (TSX: TBP, OTCQB: TBPMF) provided an update on its REDUVO™ New Drug Submission on November 16, 2022, indicating that Health Canada issued a Clarification Request regarding product labels. The response is due within the specified timeframe. REDUVO™ is aimed at treating chemotherapy-induced nausea and vomiting and expected to generate $121M in cumulative gross sales over five years. The original submission was made on December 30, 2020, and the last response was received by the end of May 2022.

Tetra Bio-Pharma announced the closing of the second tranche of a financing arrangement with Global Corporate Finance Opportunities 16, issuing $400,000 in debentures and warrants for 2,849,003 common shares at $0.0351 each. These debentures, which mature on October 26, 2023, bear no interest and are convertible into common shares at a price of 85% of the volume-weighted average price. The company faces risks regarding the ability to meet financing conditions, which may affect actual proceeds. Tetra focuses on cannabinoid-based drug development for various medical conditions.

Tetra Bio-Pharma and Prepaire submitted a $750,000 USD application to BARDA to use the Prepaire™ Shield discovery platform for exploring combination therapies involving repurposed drugs and the compound onternabez for treating chemical threat exposures. This project aims to enhance patient management following exposure to pulmonary and nerve agents, leveraging their joint expertise for innovative drug development. Onternabez, shown to reduce inflammation, could significantly impact treatment outcomes for affected patients.

Tetra Bio-Pharma has revised its financing arrangement with Alpha Blue Ocean, increasing the purchase amount of convertible debentures from $6,000,000 to $10,000,000. The company closed the first tranche of this financing, issuing $400,000 in debentures and other securities. The funds will be utilized for manufacturing costs of the QIXLEEF drug candidate, debt repayment, and working capital. The Toronto Stock Exchange has conditionally approved the listing of related shares, but the actual proceeds are uncertain, depending on conditions precedent.

Tetra Bio-Pharma has partnered with Cellvera to co-develop an oral treatment, ARDS-003, incorporating the antiviral Qifenda (Favipiravir) for COVID-19 clearance. This collaboration aims to leverage both companies' strengths to enhance therapeutic options against viral diseases. ARDS-003 demonstrated efficacy in addressing inflammation and improving outcomes in preclinical models. Favipiravir has shown sustained effectiveness against emerging SARS-CoV-2 variants, reinforcing its value in pandemic responses. The partnership signals confidence in ARDS-003’s potential to transform COVID-19 treatment.

Tetra Bio-Pharma has secured up to $6,000,000 in financing through a subscription agreement with Global Corporate Finance Opportunities 16, advised by Alpha Blue Ocean. The financing will consist of senior unsecured convertible debentures and warrants for purchasing common shares. This funding aims to support Tetra's operational costs and advance its drug development pipeline, particularly for its QIXLEEF drug candidate. The first tranche of $400,000 is expected to close soon.